Comparing of Sarepta Therapeutics Inc. (SRPT) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)

This is a contrast between Sarepta Therapeutics Inc. (NASDAQ:SRPT) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) based on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sarepta Therapeutics Inc. 125 18.55 N/A -5.94 0.00
BiondVax Pharmaceuticals Ltd. 6 0.00 N/A -2.30 0.00

Table 1 demonstrates Sarepta Therapeutics Inc. and BiondVax Pharmaceuticals Ltd.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows Sarepta Therapeutics Inc. and BiondVax Pharmaceuticals Ltd.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Sarepta Therapeutics Inc. 0.00% -43.4% -26.7%
BiondVax Pharmaceuticals Ltd. 0.00% 0% 0%

Analyst Ratings

Recommendations and Ratings for Sarepta Therapeutics Inc. and BiondVax Pharmaceuticals Ltd. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sarepta Therapeutics Inc. 0 0 10 3.00
BiondVax Pharmaceuticals Ltd. 0 0 0 0.00

$199 is Sarepta Therapeutics Inc.’s average target price while its potential upside is 131.40%.

Institutional & Insider Ownership

The shares of both Sarepta Therapeutics Inc. and BiondVax Pharmaceuticals Ltd. are owned by institutional investors at 95.9% and 0% respectively. Insiders owned roughly 0.3% of Sarepta Therapeutics Inc.’s shares. On the other hand, insiders owned about 22.93% of BiondVax Pharmaceuticals Ltd.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sarepta Therapeutics Inc. -0.37% -4.95% 28.76% 14.56% 29.09% 36.4%
BiondVax Pharmaceuticals Ltd. 7.7% 16.49% -4.82% 24.26% 5.67% 40.67%

For the past year Sarepta Therapeutics Inc. was less bullish than BiondVax Pharmaceuticals Ltd.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and CharleyÂ’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate includes M-001, a synthetic peptide-based protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is based in Ness Ziona, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.